Treatment of rheumatic diseases and hepatitis B virus coinfection

Rheumatol Int. 2015 Mar;35(3):385-92. doi: 10.1007/s00296-014-3195-8. Epub 2014 Dec 31.

Abstract

We often encounter rheumatological patients coinfected with hepatitis B in daily practice. In this paper, we will discuss the basic characteristics of the virus of hepatitis B, course of infection, the safety of rituximab, tocilizumab, abatacept treatment and therapeutic recommendations in management of patients with rheumatic diseases.

Publication types

  • Review

MeSH terms

  • Abatacept / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B e Antigens / immunology
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / immunology
  • Hepatitis B, Chronic / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Rheumatic Diseases / complications
  • Rheumatic Diseases / drug therapy*
  • Rituximab / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Antiviral Agents
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Immunosuppressive Agents
  • Rituximab
  • Abatacept
  • tocilizumab